Sign In
Buy QURE
$29.88
+3.12 (+11.66%)
At Close: Jun 03, 2026
3 Micro-Cap Stocks That Could Be Moonshots
10:31pm, Tuesday, 14'th Nov 2023
Amid the valuations of large-cap stocks, notably tech stocks in the Magnificent 7 declining, this has led to this list of micro-cap stocks. Not only are investors expected to rotate into smaller and u
Wall Street Analysts Believe uniQure (QURE) Could Rally 405.37%: Here's is How to Trade
11:16am, Wednesday, 08'th Nov 2023
The mean of analysts' price targets for uniQure (QURE) points to a 405.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst
UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates
09:46am, Tuesday, 07'th Nov 2023
UniQure (QURE) came out with a quarterly loss of $1.88 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to loss of $1.02 per share a year ago.
uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
07:05am, Tuesday, 07'th Nov 2023
~ Announced FDA clearance of Investigational New Drug (IND) application for AMT-260 in refractory mesial temporal lobe epilepsy ~
CSL and uniQure Win 2023 Prix Galien USA Award
10:00am, Friday, 27'th Oct 2023
HEMGENIX®, the first and only FDA-approved gene therapy for adults with hemophilia B, wins for Best Product for Rare/Orphan Diseases KING OF PRUSSIA, Pa. and LEXINGTON, Mass.
UniQure (QURE) Expected to Beat Earnings Estimates: Should You Buy?
11:18am, Wednesday, 25'th Oct 2023
UniQure (QURE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
07:05am, Tuesday, 24'th Oct 2023
LEXINGTON, Mass. and AMSTERDAM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,
uniQure (QURE) Up on Restructuring Plans, Workforce Reduction
12:47pm, Friday, 06'th Oct 2023
uniQure (QURE) gains on plans to discontinue investment in some projects and reduce 20% of its workforce.
Why Shares of uniQure Are Up Thursday
01:49pm, Thursday, 05'th Oct 2023
uniQure said it is cutting back 28% of its workforce. The company is discontinuing much of its pipeline to focus on more promising therapies.
uniQure slashes more than half of its research programs to preserve cash
12:21pm, Thursday, 05'th Oct 2023
Gene therapy-focused biotechnology firm uniQure announced it is slashing more than half of its research and technology projects as part of a strategic reorganization aimed at reducing its operating e
UniQure to cut 28% of workforce and scrap more than half its research projects in strategic overhaul
08:18am, Thursday, 05'th Oct 2023
UniQure N.V. QURE, -4.74%, a gene therapy company focused on developing therapies for patients with severe medical needs, said Thursday it's planning a strategic overhaul that will cut 28% of its work
uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs
07:05am, Thursday, 05'th Oct 2023
~ Reduction of 28% of workforce not related to HEMGENIX ® manufacturing obligations; Total cost savings of $180 million to extend cash runway into second quarter of 2027 ~
Why Shares of uniQure Are Dropping Tuesday
01:10pm, Tuesday, 05'th Sep 2023
The Food and Drug Administration has cleared uniQure's application for an epilepsy therapy. The company grew revenue in the second quarter by 380%, year over year.
3 Tantalizing Stocks to Buy for Under $10
03:51pm, Saturday, 26'th Aug 2023
As a rule of thumb, you should avoid targeting cheap securities, However, exceptions can always be made, particularly for these tantalizing stocks under $10 to buy. To be sure, the cheap ideas in the
UniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates
10:25am, Tuesday, 01'st Aug 2023
UniQure (QURE) came out with a quarterly loss of $1.44 per share versus the Zacks Consensus Estimate of $2.97. This compares to loss of $0.84 per share a year ago.
